Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertapenem in Indian Adults with cUTI
NCT00379951Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of ertapenem in complicated urinary tract infection (cUTI), sponsored by Merck & Co. Primary endpoint: Safety and tolerability at 14 Days. Started Jun 2005; status: completed.
02
Drugs
ertapenem
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT00379951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379951.